Lucid Diagnostics Inc. (LUCD) fundamentals score
Lucid Diagnostics is a commercial-stage cancer prevention medical diagnostics technology company. Lucid is focused on the millions of patients with gastroesophageal reflux disease (“GERD”), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma (“EAC”).
Surgical & Medical Instruments & Apparatus · Healthcare · Listed on NASDAQ
Overall: 3.4 out of 10, Unhealthy fundamentals
- Growth: 5.6/10
- Profitability: 1.0/10
- Financial health: 4.5/10
- Earnings quality: 4.0/10
- Valuation: 1.5/10
Scores are calculated from Lucid Diagnostics Inc.’s SEC filings, using the 12 months through 2025-09. Compare it with past big winners, check its flags, and see today’s price against its fundamentals in the full scorecard.
Other Healthcare stocks
- Nurix Therapeutics, Inc. (NRIX): 9.0/10
- Caredx, Inc. (CDNA): 8.9/10
- Dexcom, Inc. (DXCM): 8.8/10
- Exelixis Inc. (EXEL): 8.8/10
- Neurocrine Biosciences Inc. (NBIX): 8.7/10
- Progyny, Inc. (PGNY): 8.6/10
- Healthcare Services Group, Inc. (HCSG): 8.5/10
- Insulet Corporation (PODD): 8.5/10